UBE4B

Across TCGA pan-cancer cohorts, UBE4B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated UBE4B data layer compared with 22 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher UBE4B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated UBE4B expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where UBE4B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.504	0.850	<.001	62	view →
LSCC	OS	Quartile	All	0.959	0.572	.001	37	view →
CCRCC	OS	Median	All	0.891	0.984	.008	11	view →
LUAD	OS	Quartile	II,III,IV	0.906	0.526	.028	7	view →
HNSC	OS	Median	All	1.000	0.960	.026	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

UBE4B–PDAC (DFS)

Open the PDAC breakdown →